{"id":"almotriptan-malate","rwe":[],"tags":[],"safety":{"boxedWarnings":["Serious cardiac reactions, including myocardial infarction, have occurred following the use of almotriptan malate tablets. These reactions are extremely rare and most have been reported in patients with risk factors predictive of CAD."],"drugInteractions":[{"description":"Should not be used within 24 hours of each other due to potential additive vasospastic effects.","interaction":"Ergotamine-containing or ergot-type medications"},{"description":"Concomitant use within 24 hours is contraindicated.","interaction":"Other 5-HT1 agonists (e.g., triptans)"},{"description":"Cases of life-threatening serotonin syndrome have been reported during combined use with triptans.","interaction":"SSRIs or SNRIs"},{"description":"Use a single dose of almotriptan malate 6.25 mg; maximum almotriptan malate daily dose 12.5 mg.","interaction":"Ketoconazole"}],"commonSideEffects":[{"effect":"Sensations of pain, tightness, pressure in the chest and/or throat, neck, and jaw","drugRate":"Not specified","severity":"Moderate"}],"contraindications":["Ischemic heart disease, coronary artery vasospasm, or other significant underlying cardiovascular disease","Cerebrovascular syndromes (e.g., history of stroke or TIA)","Peripheral vascular disease (including ischemic bowel disease)","Uncontrolled hypertension","Do not use almotriptan malate within 24 hours of an ergotamine-containing, or ergot-type medication, or of another 5-HT1 agonist, e.g., another triptan","Hemiplegic or basilar migraine","Known hypersensitivity to almotriptan malate"],"specialPopulations":{"Geriatric":"No specific information provided.","Lactation":"No specific information provided.","Pediatric":"Indicated for the acute treatment of migraine headache pain in adolescents age 12 to 17 years with a history of migraine with or without aura, and who have migraine attacks usually lasting 4 hours or more.","Pregnancy":"No specific information provided."}},"trials":[],"_chembl":null,"aliases":[],"patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$20.1971/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$7,372","description":"ALMOTRIPTAN MALATE 12.5 MG TAB","retrievedDate":"2026-04-07"}],"offLabel":[],"timeline":[],"_dailymed":{"setId":"c41a4579-9db0-402b-81b1-0adf5b3978c3","title":"ALMOTRIPTAN MALATE TABLET, FILM COATED [TEVA PHARMACEUTICALS USA, INC.]"},"aiSummary":"Almotriptan malate is a 5-HT1B/1D receptor agonist used for the acute treatment of migraine attacks in adults and adolescents aged 12 to 17 years. It is contraindicated in patients with ischemic heart disease, cerebrovascular syndromes, and uncontrolled hypertension. Common side effects include sensations of pain, tightness, pressure in the chest, throat, neck, and jaw. It should not be used within 24 hours of ergotamine-containing or other 5-HT1 agonist medications.","ecosystem":[],"mechanism":{"target":"5-HT1B/1D receptors","novelty":"Almotriptan malate is a second-generation triptan with a favorable safety profile and fewer side effects compared to first-generation triptans.","modality":"Oral tablet","drugClass":"Triptan","explanation":"Almotriptan malate exerts its therapeutic effects by selectively activating 5-HT1B/1D receptors, which are located on cranial blood vessels and sensory nerve endings. This activation leads to vasoconstriction and reduced release of inflammatory mediators, thereby alleviating migraine symptoms.","oneSentence":"Almotriptan malate is a selective 5-HT1B/1D receptor agonist that binds with high affinity to these receptors, leading to vasoconstriction and inhibition of neurogenic inflammation.","technicalDetail":"Almotriptan malate binds with high affinity to 5-HT1D, 5-HT1B, and 5-HT1F receptors. It has weak affinity for 5-HT1A and 5-HT7 receptors but does not significantly bind to other serotonin receptors, adrenergic receptors, adenosine receptors, angiotensin receptors, dopamine receptors, endothelin receptors, or tachykinin receptors."},"_scrapedAt":"2026-03-28T00:38:43.657Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"yoyGrowth":"Not specified","launchDate":"Not specified","annualCostUS":"Not specified","currentRevenue":"Not specified","patientPopulation":"Adults and adolescents aged 12 to 17 years with a history of migraine","peakSalesEstimate":"Not specified"},"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"indications":{"approved":["Acute treatment of migraine attacks in adults with a history of migraine with or without aura","Acute treatment of migraine headache pain in adolescents age 12 to 17 years with a history of migraine with or without aura, and who have migraine attacks usually lasting 4 hours or more"],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT03461874","phase":"NA","title":"ACT Therapy for HF Migraine","status":"COMPLETED","sponsor":"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta","startDate":"2018-03-15","conditions":"Migraine Without Aura","enrollment":64},{"nctId":"NCT05214001","phase":"PHASE4","title":"Evaluation of the Efficacy of Almotriptan and Ubrogepant for the Acute Treatment of Migraine","status":"TERMINATED","sponsor":"Messoud Ashina, MD","startDate":"2022-06-30","conditions":"Migraine With Aura, Migraine Without Aura","enrollment":8},{"nctId":"NCT05854992","phase":"","title":"Treatments of Migraine with Triptans in Individuals with Elevated Cardiovascular Risk and in Pregnant Women","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2022-07-05","conditions":"Migraine, Cardiovascular Diseases, Pregnancy","enrollment":68419},{"nctId":"NCT01086358","phase":"PHASE4","title":"Does Treximet Improve Productivity and Patient Satisfaction Due to Sustained Response and Consistency of Response?","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2009-09","conditions":"Workplace Migraine Treatment","enrollment":60},{"nctId":"NCT01332500","phase":"","title":"Treximet ™ Pharmacy Budget Impact Model Database Validation Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-07","conditions":"Migraine Disorders","enrollment":61737},{"nctId":"NCT01435941","phase":"","title":"Non-steroidal Anti-inflammatory Drugs Alone or With a Triptan and Reports of Transition From Episodic to Chronic Migraine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09","conditions":"Migraine Disorders","enrollment":11249},{"nctId":"NCT00725140","phase":"","title":"Standardized sTudy With Almotriptan in eaRly Treatment of Migraine","status":"COMPLETED","sponsor":"Almirall, S.A.","startDate":"2008-06","conditions":"Migraine","enrollment":501},{"nctId":"NCT00257010","phase":"PHASE3","title":"A 1-year Study in Adolescents to Assess the Long-term Safety of Almotriptan Malate When Treating Their Migraine Headaches","status":"COMPLETED","sponsor":"Janssen-Ortho LLC","startDate":"2005-12","conditions":"Migraine","enrollment":447},{"nctId":"NCT01381523","phase":"","title":"A Combination Product of Sumatriptan and Naproxen Sodium Versus Single-entity Oral Triptans: An Analysis of Real World Data","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-11","conditions":"Migraine Disorders","enrollment":1},{"nctId":"NCT01381497","phase":"","title":"Impact of Migraine on Work Productivity in Patients Treated With a Combination Product Containing Sumatriptan and Naproxen Sodium or Triptan Monotherapy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-03","conditions":"Migraine Disorders","enrollment":1},{"nctId":"NCT00212823","phase":"PHASE4","title":"The Effectiveness of Almotriptan Malate (AXERT®) 12.5 Milligrams When Taken at the Onset of Migraine Pain","status":"COMPLETED","sponsor":"Ortho-McNeil Neurologics, Inc.","startDate":"2004-06","conditions":"Migraine","enrollment":1450},{"nctId":"NCT00210483","phase":"PHASE3","title":"A Study of 3 Dosage Strengths of Almotriptan Malate (AXERT®) in the Treatment of Acute Migraine in Adolescents","status":"COMPLETED","sponsor":"Janssen-Ortho LLC","startDate":"2003-07","conditions":"Migraine","enrollment":866},{"nctId":"NCT00210509","phase":"PHASE4","title":"A Study of the Effectiveness and Safety of Almotriptan Versus Placebo in the Treatment of Migraine Headache","status":"COMPLETED","sponsor":"Janssen-Ortho LLC","startDate":"2004-11","conditions":"Migraine","enrollment":378},{"nctId":"NCT00210496","phase":"PHASE4","title":"Potential Impact (Benefit) of Preventative Treatment With Topamax on the Effectiveness of Axert in the Acute Treatment of Migraine","status":"COMPLETED","sponsor":"Janssen-Ortho LLC","startDate":"2005-06","conditions":"Migraine, Classic Migraine, Common Migraine","enrollment":406},{"nctId":"NCT00208065","phase":"PHASE4","title":"Evaluation of Histamine, CGRP and VIP as Markers for Activation of Trigeminal and Parasympathetic Nerve Fibers","status":"COMPLETED","sponsor":"Clinvest","startDate":"2004-05","conditions":"Migraine, Sinusitis","enrollment":50},{"nctId":"NCT00432549","phase":"PHASE4","title":"Detoxification and Treatment of Subjects With Medication Overuse Headache","status":"UNKNOWN","sponsor":"The New England Center for Headache, P.C.","startDate":"2007-01","conditions":"Analgesic Rebound Headache","enrollment":60}],"_emaApprovals":[],"_faersSignals":[{"count":275,"reaction":"HYPERHIDROSIS"},{"count":263,"reaction":"NAUSEA"},{"count":262,"reaction":"DRUG INEFFECTIVE"},{"count":260,"reaction":"NIGHTMARE"},{"count":260,"reaction":"SEDATION"},{"count":233,"reaction":"NEPHROLITHIASIS"},{"count":202,"reaction":"OFF LABEL USE"},{"count":176,"reaction":"PRODUCT USE IN UNAPPROVED INDICATION"},{"count":36,"reaction":"FATIGUE"},{"count":35,"reaction":"HEADACHE"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"approved","brandName":"ALMOTRIPTAN MALATE","genericName":"ALMOTRIPTAN MALATE","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"2001","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2020-09-29T00:00:00.000Z","mah":"TEVA PHARMS USA","brand_name_local":null,"application_number":"ANDA078027"},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}